Cephalexin and Movicol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cephalexin (cephalexin) and Movicol (polyethylene glycol 3350). Common drug interactions include nausea among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Cephalexin and Movicol. It is created by eHealthMe based on reports of 37 people who take the same drugs from the FDA, and is updated regularly.

What is Cephalexin?

Cephalexin has active ingredients of cephalexin. It is often used in infection. eHealthMe is studying from 30,580 Cephalexin users. Check the latest studies of Cephalexin.

What is Movicol?

Movicol has active ingredients of polyethylene glycol 3350. It is often used in constipation. eHealthMe is studying from 14,249 Movicol users. Check the latest studies of Movicol.



On Jul, 17, 2026

37 people who take Cephalexin and Movicol together, and have interactions are studied.

Cephalexin and Movicol drug interactions.

What are the common drug interactions of Cephalexin and Movicol, by gender? *:

female:

  1. Nausea (feeling of having an urge to vomit)
  2. Dyspnoea (difficult or laboured respiration)
  3. Cardiac failure
  4. Cough
  5. Crepitations (noises are produced by the rubbing of parts one against the other)
  6. Dizziness exertional
  7. Febrile neutropenia (fever with reduced white blood cells)
  8. Infective exacerbation of chronic obstructive airways disease (severe infective lung disease with chronic obstructive airways disease)
  9. Neck pain
  10. Oedema peripheral (superficial swelling)

male:

  1. Death
  2. Chest pain
  3. Venous thrombosis limb (blood clot that forms in a vein in the limb)
  4. Chills (felling of cold)
  5. Decreased appetite
  6. Dizziness
  7. Incontinence (lack of moderation or self-control)
  8. Pyrexia (fever)
  9. Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
  10. Febrile neutropenia (fever with reduced white blood cells)

What are the common drug interactions of Cephalexin and Movicol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Death

10-19:

  1. Umbilical hernia (an outward bulging (protrusion) of the abdominal lining or part of the abdominal organ(s) through the area around the belly button)
  2. Feeding disorder (when children refuse to eat certain food groups)

20-29:

n/a

30-39:

  1. Drug hypersensitivity

40-49:

  1. Acute myocardial infarction (acute heart attack)
  2. Catheter site infection (infection at the site of insertion)
  3. Hypotension (abnormally low blood pressure)
  4. Sepsis (a severe blood infection that can lead to organ failure and death)

50-59:

  1. Dyspnoea (difficult or laboured respiration)
  2. Cardiac failure
  3. Cough
  4. Crepitations (noises are produced by the rubbing of parts one against the other)
  5. Dizziness exertional
  6. Infective exacerbation of chronic obstructive airways disease (severe infective lung disease with chronic obstructive airways disease)
  7. Oedema peripheral (superficial swelling)
  8. Productive cough
  9. Weight decreased
  10. Weight increased

60+:

  1. Febrile neutropenia (fever with reduced white blood cells)
  2. Chest pain
  3. Pneumonia
  4. Venous thrombosis limb (blood clot that forms in a vein in the limb)
  5. Chills (felling of cold)
  6. Decreased appetite
  7. Dizziness
  8. Incontinence (lack of moderation or self-control)
  9. Pyrexia (fever)
  10. Asthma

What are the existing conditions these people have? *

  1. Pain: 16 people, 43.24%
  2. Nausea (feeling of having an urge to vomit): 15 people, 40.54%
  3. High Blood Pressure: 12 people, 32.43%
  4. Pneumonia: 10 people, 27.03%
  5. Cough: 9 people, 24.32%
  6. Lower Respiratory Tract Infection: 9 people, 24.32%
  7. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 21.62%
  8. Fever: 6 people, 16.22%
  9. Cellulitis (infection under the skin): 6 people, 16.22%
  10. Asthma: 6 people, 16.22%

* Approximation only. Some reports may have incomplete information.

Do you take Cephalexin and Movicol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cephalexin and Movicol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cephalexin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Movicol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cephalexin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Movicol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on cephalexin and polyethylene glycol 3350 (the active ingredients of Cephalexin and Movicol, respectively), and Cephalexin and Movicol (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: